Peptide Synthesis Market by Instruments (Synthesizers, Purification, Lyophilizers, Analytical), Reagents (Amino Acids, Resins), Technique (Chemical, Biological), Services (Custom Synthesis, Modification), Application, End User - Global Forecast to 2031
The global peptide synthesis market is estimated to reach USD 1.54 billion by 2031 from USD 0.98 billion in 2026, at a CAGR of 9.5% from 2026 to 2031. The market is projected to grow steadily over the forecast period, driven by the expanding pipeline of peptide-based therapeutics, rising demand for GLP-1 and other metabolic peptides, and broader use of synthetic peptides in oncology, diagnostics, and research. Growth is further supported by advances in automated solid-phase peptide synthesis, high-throughput platforms, specialized modification chemistries, and peptide purification and analytical technologies. However, high material and solvent consumption, synthesis complexity for long and difficult sequences, purification challenges, and the need for specialized technical expertise are expected to restrain broader market growth.
The primary interviews conducted for this report can be categorized as follows:
“The custom peptide synthesis services segment accounted for the largest share, by service type, in 2025.”
Based on service type, the peptide synthesis services market is segmented into custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, and peptide library preparation/synthesis services. In 2025, custom peptide synthesis services accounted for the largest market share, driven by growing outsourcing of standard, high-purity, modified, long, and complex peptide requirements. These services are widely used across drug discovery, therapeutic development, diagnostic research, antibody generation, and academic research workflows. Demand is further supported by increasing requirements for rapid turnaround, customized purity levels, difficult sequences, and specialized peptide formats. Their broad applicability across pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes continues to support the segment’s leading position globally.“Chemical synthesis segment accounted for the largest share of the peptide synthesis products market, by technique, in 2025.”
Based on technique, the peptide synthesis products market is segmented into chemical synthesis and biological synthesis. Chemical synthesis accounted for the largest market share in 2025, due to the widespread use of solid-phase peptide synthesis (SPPS) for research and therapeutic peptide production. SPPS offers established Fmoc- and Boc-based chemistries, compatibility with automation, sequence flexibility, and a broad ecosystem of synthesizers, resins, protected amino acids, and coupling reagents. Liquid-phase synthesis, hybrid approaches, and chemical ligation methods complement SPPS for selected fragments and complex sequences. The maturity of chemical synthesis workflows and their extensive use across pharmaceutical, biotechnology, CRO, and academic laboratories continue to support the segment’s leading position.“Asia Pacific is expected to register the highest CAGR in the peptide synthesis market from 2026 to 2031.”
The peptide synthesis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to grow at the highest CAGR during the forecast period, driven by expanding pharmaceutical and biotechnology R&D, growing peptide drug development, rising outsourcing of custom peptide synthesis, and improvements in research infrastructure. Growth is further supported by increasing adoption of automated peptide synthesizers, advanced purification and analytical platforms, and expanding demand for peptide therapeutics across China, India, Japan, South Korea, and Australia. Established regional suppliers and expanding global life-science operations continue to strengthen peptide synthesis capabilities across the region.The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (80%) and Demand Side (20%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Research Coverage
This research report categorizes the peptide synthesis market by offering (products, services), product type (instruments, reagents & consumables), technique (chemical synthesis, biological synthesis), service type (custom peptide synthesis services, peptide engineering & modification services, peptide purification services, peptide analytical & characterization services, peptide library preparation/synthesis services), application (therapeutic applications, diagnostics applications, research applications), product end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), service end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, medical device companies, clinical & diagnostic laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the peptide synthesis market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product & services portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the peptide synthesis market.Key Benefits of Buying the Report
This report offers a comprehensive overview of the peptide synthesis market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies:The report provides insights on the following pointers
- Analysis of key drivers (surging demand for GLP-1 and other high-volume peptide therapeutics, rising complexity of peptide modalities requiring advanced synthesis and purification, expanding peptide drug pipelines and clinical development activity), restraints (high material consumption and waste generation in large-scale peptide synthesis, high cost and supply sensitivity of GMP-grade synthesis inputs), opportunities (rapid expansion of global GMP peptide manufacturing capacity, shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies), and challenges (maintaining yield, purity, and batch consistency for complex peptides at scale) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products & services of the peptide synthesis market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the peptide synthesis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), Kaneka Corporation (Japan), Biotage AB (Sweden), Sartorius AG (Germany), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), GL Biochem (Shanghai) Ltd. (China), Mesa Laboratories, Inc. (US), Danaher Corporation (US), Chem-Impex International, Inc. (US), Advanced ChemTech (ACT) (US), Mimotopes Pty Ltd (Australia), Iris Biotech GmbH (Germany), AAPPTec, LLC (US), Enamine Ltd. (Ukraine), Intavis Peptide Services (Germany), JPT Peptide Technologies GmbH (Germany), Innovagen AB (Sweden), Peptide Protein Research Ltd. (UK), LifeTein LLC (US), Creative Peptides (US), Genemed Synthesis, Inc. (US), ChinaPeptides Co., Ltd. (China), and Beijing Scilight Biotechnology Co., Ltd. (China).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PEPTIDE SYNTHESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 PEPTIDE SYNTHESIS MARKET OVERVIEW
3.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING
3.3 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 PEPTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Surging demand for GLP-1 and other high-volume peptide therapeutics
4.2.1.2 Rising complexity of peptide modalities requiring advanced synthesis and purification
4.2.1.3 Expanding peptide drug pipelines and clinical development activity
4.2.2 RESTRAINTS
4.2.2.1 High material consumption and waste generation in large-scale solid-phase peptide synthesis
4.2.2.2 High cost and supply sensitivity of GMP-grade synthesis inputs
4.2.3 OPPORTUNITIES
4.2.3.1 Rapid expansion of global GMP peptide manufacturing capacity
4.2.3.2 Shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies
4.2.4 CHALLENGES
4.2.4.1 Maintaining yield, purity, and batch consistency for complex peptides at scale
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL PEPTIDE SYNTHESIS MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 902720)
5.6.2 EXPORT SCENARIO (HS CODE 902720)
5.6.3 IMPORT SCENARIO (HS CODE 841933)
5.6.4 EXPORT SCENARIO (HS CODE 841933)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING ACTIVITY
5.10 IMPACT OF 2025 US TARIFFS ON PEPTIDE SYNTHESIS MARKET
5.10.1 INTRODUCTION
5.10.2 PRICE IMPACT ANALYSIS
5.10.3 IMPACT ON COUNTRY/REGION
5.10.3.1 North America
5.10.3.2 Europe
5.10.3.3 Asia Pacific
5.10.4 IMPACT ON END-USE INDUSTRIES
5.10.4.1 Pharmaceutical & biotechnology companies
5.10.4.2 CROs & CDMOs
5.10.4.3 Academic & research institutes, diagnostic labs, and other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Solid-phase peptide synthesis (SPPS)
6.1.1.2 Liquid-phase peptide synthesis (LPPS)
6.1.1.3 Enzymatic peptide synthesis
6.1.1.4 Recombinant peptide synthesis
6.1.1.5 Continuous-flow peptide synthesis
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Analytical characterization & quality-control technologies
6.1.2.2 Purification & downstream processing technologies
6.1.2.3 Peptide ligation technologies
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Protein design & engineering
6.1.3.2 Synthetic biology/genetic-code engineering
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
6.5.1 BEST PRACTICES IN PEPTIDE SYNTHESIS WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 PEPTIDE SYNTHESIS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 IN-HOUSE WORKFLOW CONTROL AND RECURRING PEPTIDE-SPECIFIC DEMAND TO DRIVE MARKET GROWTH
9.3 SERVICES
9.3.1 GROWING OUTSOURCING OF COMPLEX AND VARIABLE-VOLUME PEPTIDE PROJECTS TO SUPPORT MARKET GROWTH
10 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE
10.1 INTRODUCTION
10.2 REAGENTS & CONSUMABLES
10.2.1 REAGENTS
10.2.1.1 Amino acid building blocks
10.2.1.1.1 Expanding use of protected and non-natural residues to drive demand for amino acid building blocks
10.2.1.2 Resins
10.2.1.2.1 Broader linker chemistry and high-throughput SPPS formats to support steady resin demand
10.2.1.3 Coupling reagents
10.2.1.3.1 Need for faster activation and lower side-reaction risk to sustain demand for advanced coupling chemistry
10.2.1.4 Peptide modification reagents
10.2.1.4.1 Half-life extension, targeting, and conjugation strategies to make modification reagents fastest-growing reagent category
10.2.1.5 Labeling reagents
10.2.1.5.1 Rising use of labeled peptides in imaging, diagnostics, binding studies, and assay development to expand demand
10.2.1.6 Protection & deprotection reagents
10.2.1.6.1 Orthogonal protecting strategies and pressure to reduce hazardous chemistry to shape product selection
10.2.1.7 Cleavage reagents
10.2.1.7.1 Continued SPPS use and demand for cleaner cleavage profiles to support recurring cleavage-chemistry purchases
10.2.1.8 Other reagents
10.2.2 CONSUMABLES
10.2.2.1 Higher synthesis throughput and purification workload to support steady recurring consumables demand
10.3 INSTRUMENTS
10.3.1 PEPTIDE SYNTHESIZERS
10.3.1.1 Peptide synthesizers, by type
10.3.1.1.1 Automated peptide synthesizers
10.3.1.1.2 Manual peptide synthesizers
10.3.1.2 Peptide synthesizers, by technology
10.3.1.2.1 Conventional-batch peptide synthesizers
10.3.1.2.2 Microwave-assisted peptide synthesizers
10.3.1.2.3 Hybrid peptide synthesizers
10.3.1.2.4 Other peptide synthesizers
10.3.2 PURIFICATION SYSTEMS
10.3.2.1 Higher crude-peptide complexity and throughput bottlenecks to increase demand for scalable purification platforms
10.3.3 ANALYTICAL & QUALITY CONTROL INSTRUMENTS
10.3.3.1 Impurity profiling, identity confirmation, and tighter peptide quality requirements to sustain analytical platform investment
10.3.4 LYOPHILIZATION EQUIPMENT
10.3.4.1 Need for stable dry peptide formats and scale-appropriate freeze-drying capacity to support demand
10.3.5 OTHER INSTRUMENTS
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE
11.1 INTRODUCTION
11.2 CHEMICAL SYNTHESIS
11.2.1 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS)
11.2.1.1 Automation, rapid iterative chemistry, and commercial-scale familiarity to sustain SPPS as largest chemical synthesis method
11.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS)
11.2.2.1 Solvent-efficiency improvements and large-scale economics to make LPPS fastest-growing chemical synthesis method
11.2.3 OTHER CHEMICAL METHODS
11.3 BIOLOGICAL SYNTHESIS
11.3.1 RECOMBINANT PEPTIDE PRODUCTION
11.3.1.1 Scalable microbial expression and established biologics infrastructure to keep recombinant production dominant within biological synthesis
11.3.2 ENZYMATIC PEPTIDE SYNTHESIS
11.3.2.1 High selectivity and lower-solvent ligation to position enzymatic synthesis as fastest-growing biological method
12 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1 EXPANDING PEPTIDE PIPELINES AND IN-HOUSE MANUFACTURING CAPABILITIES TO DRIVE MARKET GROWTH
12.3 CROS & CDMOS
12.3.1 RAPID OUTSOURCING AND CAPACITY EXPANSION TO MAKE CROS & CDMOS FASTEST-GROWING PRODUCT END-USER CATEGORY
12.4 ACADEMIC & RESEARCH INSTITUTES
12.4.1 DISCOVERY-LED PEPTIDE LIBRARIES AND GREATER ACCESS TO AUTOMATED BENCHTOP SYSTEMS TO SUSTAIN RESEARCH INSTITUTE DEMAND
12.5 MEDICAL DEVICE COMPANIES
12.5.1 PEPTIDE-FUNCTIONALIZED BIOSENSORS AND SURFACE-ENGINEERED DEVICES TO BROADEN SPECIALIZED DEMAND FOR MODIFIED SYNTHESIS PRODUCTS
12.6 CLINICAL & DIAGNOSTIC LABORATORIES
12.6.1 HIGHER ASSAY SPECIFICITY AND STANDARDIZED PEPTIDE REAGENTS TO SUPPORT ADOPTION IN CLINICAL AND DIAGNOSTIC LABORATORIES
13 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE
13.1 INTRODUCTION
13.2 CUSTOM PEPTIDE SYNTHESIS SERVICES
13.2.1 FLEXIBLE SEQUENCE, PURITY, AND QUANTITY REQUIREMENTS TO KEEP CUSTOM PEPTIDE SYNTHESIS SERVICES LARGEST SERVICE CATEGORY
13.3 PEPTIDE ENGINEERING & MODIFICATION SERVICES
13.3.1 GROWING NEED FOR HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION TO MAKE ENGINEERING & MODIFICATION SERVICES FASTEST-GROWING CATEGORY
13.4 PEPTIDE PURIFICATION SERVICES
13.4.1 MORE DIFFICULT PEPTIDE SEQUENCES AND TIGHTER PURITY SPECIFICATIONS TO SUSTAIN DEMAND FOR OUTSOURCED PURIFICATION
13.5 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES
13.5.1 RISING MOLECULAR COMPLEXITY AND QUALITY EXPECTATIONS TO EXPAND PEPTIDE ANALYTICAL & CHARACTERIZATION OUTSOURCING
13.6 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES
13.6.1 HIGH-THROUGHPUT SCREENING AND IMMUNE-MONITORING WORKFLOWS TO INCREASE ADOPTION OF PEPTIDE LIBRARY SERVICES
14 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 BROAD OUTSOURCING ACROSS DISCOVERY AND DEVELOPMENT TO BOOST MARKET GROWTH
14.3 CROS & CDMOS
14.3.1 EXTERNAL CAPACITY, SPECIALIZED CHEMISTRY, AND NETWORK FLEXIBILITY TO MAKE CROS & CDMOS FASTEST-GROWING SERVICE END-USER CATEGORY
14.4 ACADEMIC & RESEARCH INSTITUTES
14.4.1 FLEXIBLE PROJECT-SCALE OUTSOURCING AND SPECIALIZED PEPTIDE FORMATS TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
14.5 MEDICAL DEVICE COMPANIES
14.5.1 PEPTIDE-FUNCTIONALIZED DEVICES AND BIOSENSORS TO INCREASE DEMAND FOR SPECIALIZED SYNTHESIS, MODIFICATION, AND CONJUGATION SERVICES
14.6 CLINICAL & DIAGNOSTIC LABORATORIES
14.6.1 ASSAY STANDARDIZATION AND CLINICAL-GRADE QUALITY REQUIREMENTS TO SUPPORT OUTSOURCED PEPTIDE SERVICES FOR DIAGNOSTIC LABORATORIES
15 PEPTIDE SYNTHESIS MARKET, BY APPLICATION
15.1 INTRODUCTION
15.2 THERAPEUTIC APPLICATIONS
15.2.1 THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION
15.2.1.1 Diabetes
15.2.1.1.1 Large established peptide classes and sustained need for high-purity analogs drive growth
15.2.1.2 Obesity
15.2.1.2.1 Late-stage dual- and triple-agonist pipelines and rapid commercial scale-up to make obesity fastest-growing therapeutic indication
15.2.1.3 Cancer
15.2.1.3.1 Targeted delivery, neoantigen programs, and radioligand development to deepen peptide-synthesis requirements in oncology
15.2.1.4 Autoimmune disease
15.2.1.4.1 Targeted oral peptides and antigen-specific immunomodulation to broaden peptide use in chronic autoimmune disorders
15.2.1.5 Other therapeutic indications
15.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE
15.2.2.1 Metabolic & hormonal peptides
15.2.2.1.1 High-volume incretin, insulin, and hormone-peptide demand to drive market growth
15.2.2.2 Peptide inhibitors
15.2.2.2.1 Improved oral delivery, structural constraint, and access to difficult protein interfaces to expand peptide inhibitor development
15.2.2.3 Peptide-drug conjugates (PDCs)
15.2.2.3.1 Targeted payload delivery and radioconjugate pipelines to make PDCs fastest-growing therapeutic molecule category
15.2.2.4 Peptide-based vaccines
15.2.2.4.1 Neoepitope discovery, immune monitoring, and personalized vaccine strategies to support high-diversity peptide synthesis demand
15.2.2.5 Other therapeutic modalities
15.3 RESEARCH APPLICATIONS
15.3.1 HIGH-THROUGHPUT DISCOVERY, BIOMARKER STUDIES, AND RECURRING CUSTOM-PEPTIDE USE TO SUSTAIN BROAD RESEARCH DEMAND BASE
15.4 DIAGNOSTIC APPLICATIONS
15.4.1 PEPTIDE-BASED ASSAY REAGENTS, IMAGING LIGANDS, AND COMPANION-DIAGNOSTIC DEVELOPMENT TO EXPAND SPECIALIZED DIAGNOSTIC DEMAND
16 PEPTIDE SYNTHESIS MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 US
16.2.1.1 Dense peptide pipelines and domestic capacity to sustain market growth
16.2.2 CANADA
16.2.2.1 Biopharma manufacturing investment and research demand to support steady expansion
16.3 EUROPE
16.3.1 GERMANY
16.3.1.1 Integrated peptide manufacturing and strong chemical supply chains to support demand
16.3.2 UK
16.3.2.1 Research intensity and diagnostic peptide capability to support specialized demand
16.3.3 FRANCE
16.3.3.1 Expanding SPPS capacity to strengthen commercial peptide supply base
16.3.4 ITALY
16.3.4.1 Injectable manufacturing integration to support peptide development-to-product workflows
16.3.5 SPAIN
16.3.5.1 Research and specialty-pharma activity to sustain demand for imported synthesis solutions
16.3.6 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 CHINA
16.4.1.1 Large-scale TIDES capacity and domestic supplier depth to accelerate market expansion
16.4.2 JAPAN
16.4.2.1 Advanced drug discovery and specialty peptide innovation to sustain high-value demand
16.4.3 INDIA
16.4.3.1 Cost-efficient CRDMO expansion and new peptide capacity to accelerate market growth
16.4.4 SOUTH KOREA
16.4.4.1 Biotech investment and long-acting peptide development to expand specialized demand
16.4.5 AUSTRALIA
16.4.5.1 Research-intensive institutions and biotech pipelines to sustain high-value peptide demand
16.4.6 REST OF ASIA PACIFIC
16.5 LATIN AMERICA
16.5.1 BRAZIL
16.5.1.1 Large research base and metabolic-disease focus to make Brazil core Latin American market
16.5.2 MEXICO
16.5.2.1 US-linked manufacturing and clinical research to support peptide synthesis demand
16.5.3 REST OF LATIN AMERICA
16.6 MIDDLE EAST
16.6.1 GCC COUNTRIES
16.6.1.1 Saudi Arabia
16.6.1.1.1 Localization initiatives and research funding to support rising peptide workflow adoption
16.6.1.2 UAE
16.6.1.2.1 Biotech hubs and regional distribution to strengthen access to peptide synthesis solutions
16.6.1.3 Rest of GCC Countries
16.6.2 REST OF MIDDLE EAST
16.7 AFRICA
16.7.1 RESEARCH-LED DEMAND AND IMPORT DEPENDENCE TO SHAPE MARKET
17 COMPETITIVE LANDSCAPE
17.1 OVERVIEW
17.2 KEY PLAYER STRATEGY/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
17.3 REVENUE ANALYSIS, 2021–2025
17.4 MARKET SHARE ANALYSIS, 2025
17.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Offering footprint
17.5.5.4 Product type footprint
17.5.5.5 Application footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of key startups/SMEs
17.7 COMPANY VALUATION & FINANCIAL METRICS
17.7.1 FINANCIAL METRICS
17.7.2 COMPANY VALUATION
17.8 PRODUCT/SERVICE COMPARISON
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT LAUNCHES
17.9.2 DEALS
17.9.3 EXPANSIONS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 THERMO FISHER SCIENTIFIC INC.
18.1.1.1 Business overview
18.1.1.2 Products & services offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches
18.1.1.3.2 Deals
18.1.1.3.3 Expansions
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses & competitive threats
18.1.2 MERCK KGAA
18.1.2.1 Business overview
18.1.2.2 Products & services offered
18.1.2.3 Recent developments
18.1.2.3.1 Deals
18.1.2.3.2 Expansions
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 AGILENT TECHNOLOGIES, INC.
18.1.3.1 Business overview
18.1.3.2 Products & services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses and competitive threats
18.1.4 GENSCRIPT BIOTECH CORPORATION
18.1.4.1 Business overview
18.1.4.2 Products & services offered
18.1.4.3 Recent developments
18.1.4.3.1 Expansions
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 KANEKA CORPORATION
18.1.5.1 Business overview
18.1.5.2 Products & services offered
18.1.5.3 Recent developments
18.1.5.3.1 Expansions
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 SARTORIUS AG
18.1.6.1 Business overview
18.1.6.2 Products & services offered
18.1.6.3 Recent developments
18.1.6.3.1 Expansions
18.1.7 BACHEM HOLDING AG
18.1.7.1 Business overview
18.1.7.2 Products & services offered
18.1.7.3 Recent developments
18.1.7.3.1 Deals
18.1.7.3.2 Expansions
18.1.8 BIOTAGE AB
18.1.8.1 Business overview
18.1.8.2 Products & services offered
18.1.8.3 Recent developments
18.1.8.3.1 Product launches
18.1.8.3.2 Deals
18.1.9 CEM CORPORATION
18.1.9.1 Business overview
18.1.9.2 Products & services offered
18.1.9.3 Recent developments
18.1.9.3.1 Product launches
18.1.10 BIO-SYNTHESIS, INC.
18.1.10.1 Business overview
18.1.10.2 Products & services offered
18.1.11 BIOSYNTH
18.1.11.1 Business overview
18.1.11.2 Products & services offered
18.1.11.3 Recent developments
18.1.11.3.1 Deals
18.1.11.3.2 Expansions
18.1.12 CSBIO
18.1.12.1 Business overview
18.1.12.2 Products & services offered
18.1.13 GL BIOCHEM (SHANGHAI) LTD.
18.1.13.1 Business overview
18.1.13.2 Products & services offered
18.1.14 MESA LABORATORIES, INC.
18.1.14.1 Business overview
18.1.14.2 Products & services offered
18.1.14.3 Recent developments
18.1.14.3.1 Product & service launches
18.1.14.3.2 Deals
18.1.15 DANAHER CORPORATION
18.1.15.1 Business overview
18.1.15.2 Products & services offered
18.1.15.3 Recent developments
18.1.15.3.1 Product launches
18.2 OTHER PLAYERS
18.2.1 CHEM-IMPEX INTERNATIONAL, INC.
18.2.2 ADVANCED CHEMTECH
18.2.3 MIMOTOPES PTY LTD.
18.2.4 IRIS BIOTECH GMBH
18.2.5 AAPPTEC, LLC
18.2.6 ENAMINE LTD.
18.2.7 INTAVIS PEPTIDE SERVICES GMBH
18.2.8 JPT PEPTIDE TECHNOLOGIES GMBH
18.2.9 INNOVAGEN AB
18.2.10 PEPTIDE PROTEIN RESEARCH LTD.
18.2.11 LIFETEIN LLC
18.2.12 CREATIVE PEPTIDES
18.2.13 GENEMED SYNTHESIS, INC.
18.2.14 CHINAPEPTIDES CO., LTD.
18.2.15 BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO.
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.1.1 SECONDARY DATA
19.1.1.1 Key secondary sources
19.1.1.2 Key data from secondary research
19.1.2 PRIMARY DATA
19.1.2.1 Key primary participants
19.1.2.2 Breakdown of primary interviews
19.1.2.3 Key data from primary sources
19.2 MARKET SIZE ESTIMATION
19.2.1 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
19.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
19.2.1.2 Approach 2: Primary research
19.2.1.2.1 Key industry insights
19.2.1.3 Approach 3: MnM repository analysis
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
19.3 MARKET GROWTH RATE PROJECTIONS
19.4 DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PEPTIDE SYNTHESIS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 PEPTIDE SYNTHESIS MARKET OVERVIEW
3.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING
3.3 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 PEPTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Surging demand for GLP-1 and other high-volume peptide therapeutics
4.2.1.2 Rising complexity of peptide modalities requiring advanced synthesis and purification
4.2.1.3 Expanding peptide drug pipelines and clinical development activity
4.2.2 RESTRAINTS
4.2.2.1 High material consumption and waste generation in large-scale solid-phase peptide synthesis
4.2.2.2 High cost and supply sensitivity of GMP-grade synthesis inputs
4.2.3 OPPORTUNITIES
4.2.3.1 Rapid expansion of global GMP peptide manufacturing capacity
4.2.3.2 Shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies
4.2.4 CHALLENGES
4.2.4.1 Maintaining yield, purity, and batch consistency for complex peptides at scale
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL PEPTIDE SYNTHESIS MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 902720)
5.6.2 EXPORT SCENARIO (HS CODE 902720)
5.6.3 IMPORT SCENARIO (HS CODE 841933)
5.6.4 EXPORT SCENARIO (HS CODE 841933)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING ACTIVITY
5.10 IMPACT OF 2025 US TARIFFS ON PEPTIDE SYNTHESIS MARKET
5.10.1 INTRODUCTION
5.10.2 PRICE IMPACT ANALYSIS
5.10.3 IMPACT ON COUNTRY/REGION
5.10.3.1 North America
5.10.3.2 Europe
5.10.3.3 Asia Pacific
5.10.4 IMPACT ON END-USE INDUSTRIES
5.10.4.1 Pharmaceutical & biotechnology companies
5.10.4.2 CROs & CDMOs
5.10.4.3 Academic & research institutes, diagnostic labs, and other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Solid-phase peptide synthesis (SPPS)
6.1.1.2 Liquid-phase peptide synthesis (LPPS)
6.1.1.3 Enzymatic peptide synthesis
6.1.1.4 Recombinant peptide synthesis
6.1.1.5 Continuous-flow peptide synthesis
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Analytical characterization & quality-control technologies
6.1.2.2 Purification & downstream processing technologies
6.1.2.3 Peptide ligation technologies
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Protein design & engineering
6.1.3.2 Synthetic biology/genetic-code engineering
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
6.5.1 BEST PRACTICES IN PEPTIDE SYNTHESIS WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 PEPTIDE SYNTHESIS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 IN-HOUSE WORKFLOW CONTROL AND RECURRING PEPTIDE-SPECIFIC DEMAND TO DRIVE MARKET GROWTH
9.3 SERVICES
9.3.1 GROWING OUTSOURCING OF COMPLEX AND VARIABLE-VOLUME PEPTIDE PROJECTS TO SUPPORT MARKET GROWTH
10 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE
10.1 INTRODUCTION
10.2 REAGENTS & CONSUMABLES
10.2.1 REAGENTS
10.2.1.1 Amino acid building blocks
10.2.1.1.1 Expanding use of protected and non-natural residues to drive demand for amino acid building blocks
10.2.1.2 Resins
10.2.1.2.1 Broader linker chemistry and high-throughput SPPS formats to support steady resin demand
10.2.1.3 Coupling reagents
10.2.1.3.1 Need for faster activation and lower side-reaction risk to sustain demand for advanced coupling chemistry
10.2.1.4 Peptide modification reagents
10.2.1.4.1 Half-life extension, targeting, and conjugation strategies to make modification reagents fastest-growing reagent category
10.2.1.5 Labeling reagents
10.2.1.5.1 Rising use of labeled peptides in imaging, diagnostics, binding studies, and assay development to expand demand
10.2.1.6 Protection & deprotection reagents
10.2.1.6.1 Orthogonal protecting strategies and pressure to reduce hazardous chemistry to shape product selection
10.2.1.7 Cleavage reagents
10.2.1.7.1 Continued SPPS use and demand for cleaner cleavage profiles to support recurring cleavage-chemistry purchases
10.2.1.8 Other reagents
10.2.2 CONSUMABLES
10.2.2.1 Higher synthesis throughput and purification workload to support steady recurring consumables demand
10.3 INSTRUMENTS
10.3.1 PEPTIDE SYNTHESIZERS
10.3.1.1 Peptide synthesizers, by type
10.3.1.1.1 Automated peptide synthesizers
10.3.1.1.2 Manual peptide synthesizers
10.3.1.2 Peptide synthesizers, by technology
10.3.1.2.1 Conventional-batch peptide synthesizers
10.3.1.2.2 Microwave-assisted peptide synthesizers
10.3.1.2.3 Hybrid peptide synthesizers
10.3.1.2.4 Other peptide synthesizers
10.3.2 PURIFICATION SYSTEMS
10.3.2.1 Higher crude-peptide complexity and throughput bottlenecks to increase demand for scalable purification platforms
10.3.3 ANALYTICAL & QUALITY CONTROL INSTRUMENTS
10.3.3.1 Impurity profiling, identity confirmation, and tighter peptide quality requirements to sustain analytical platform investment
10.3.4 LYOPHILIZATION EQUIPMENT
10.3.4.1 Need for stable dry peptide formats and scale-appropriate freeze-drying capacity to support demand
10.3.5 OTHER INSTRUMENTS
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE
11.1 INTRODUCTION
11.2 CHEMICAL SYNTHESIS
11.2.1 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS)
11.2.1.1 Automation, rapid iterative chemistry, and commercial-scale familiarity to sustain SPPS as largest chemical synthesis method
11.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS)
11.2.2.1 Solvent-efficiency improvements and large-scale economics to make LPPS fastest-growing chemical synthesis method
11.2.3 OTHER CHEMICAL METHODS
11.3 BIOLOGICAL SYNTHESIS
11.3.1 RECOMBINANT PEPTIDE PRODUCTION
11.3.1.1 Scalable microbial expression and established biologics infrastructure to keep recombinant production dominant within biological synthesis
11.3.2 ENZYMATIC PEPTIDE SYNTHESIS
11.3.2.1 High selectivity and lower-solvent ligation to position enzymatic synthesis as fastest-growing biological method
12 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1 EXPANDING PEPTIDE PIPELINES AND IN-HOUSE MANUFACTURING CAPABILITIES TO DRIVE MARKET GROWTH
12.3 CROS & CDMOS
12.3.1 RAPID OUTSOURCING AND CAPACITY EXPANSION TO MAKE CROS & CDMOS FASTEST-GROWING PRODUCT END-USER CATEGORY
12.4 ACADEMIC & RESEARCH INSTITUTES
12.4.1 DISCOVERY-LED PEPTIDE LIBRARIES AND GREATER ACCESS TO AUTOMATED BENCHTOP SYSTEMS TO SUSTAIN RESEARCH INSTITUTE DEMAND
12.5 MEDICAL DEVICE COMPANIES
12.5.1 PEPTIDE-FUNCTIONALIZED BIOSENSORS AND SURFACE-ENGINEERED DEVICES TO BROADEN SPECIALIZED DEMAND FOR MODIFIED SYNTHESIS PRODUCTS
12.6 CLINICAL & DIAGNOSTIC LABORATORIES
12.6.1 HIGHER ASSAY SPECIFICITY AND STANDARDIZED PEPTIDE REAGENTS TO SUPPORT ADOPTION IN CLINICAL AND DIAGNOSTIC LABORATORIES
13 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE
13.1 INTRODUCTION
13.2 CUSTOM PEPTIDE SYNTHESIS SERVICES
13.2.1 FLEXIBLE SEQUENCE, PURITY, AND QUANTITY REQUIREMENTS TO KEEP CUSTOM PEPTIDE SYNTHESIS SERVICES LARGEST SERVICE CATEGORY
13.3 PEPTIDE ENGINEERING & MODIFICATION SERVICES
13.3.1 GROWING NEED FOR HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION TO MAKE ENGINEERING & MODIFICATION SERVICES FASTEST-GROWING CATEGORY
13.4 PEPTIDE PURIFICATION SERVICES
13.4.1 MORE DIFFICULT PEPTIDE SEQUENCES AND TIGHTER PURITY SPECIFICATIONS TO SUSTAIN DEMAND FOR OUTSOURCED PURIFICATION
13.5 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES
13.5.1 RISING MOLECULAR COMPLEXITY AND QUALITY EXPECTATIONS TO EXPAND PEPTIDE ANALYTICAL & CHARACTERIZATION OUTSOURCING
13.6 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES
13.6.1 HIGH-THROUGHPUT SCREENING AND IMMUNE-MONITORING WORKFLOWS TO INCREASE ADOPTION OF PEPTIDE LIBRARY SERVICES
14 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 BROAD OUTSOURCING ACROSS DISCOVERY AND DEVELOPMENT TO BOOST MARKET GROWTH
14.3 CROS & CDMOS
14.3.1 EXTERNAL CAPACITY, SPECIALIZED CHEMISTRY, AND NETWORK FLEXIBILITY TO MAKE CROS & CDMOS FASTEST-GROWING SERVICE END-USER CATEGORY
14.4 ACADEMIC & RESEARCH INSTITUTES
14.4.1 FLEXIBLE PROJECT-SCALE OUTSOURCING AND SPECIALIZED PEPTIDE FORMATS TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
14.5 MEDICAL DEVICE COMPANIES
14.5.1 PEPTIDE-FUNCTIONALIZED DEVICES AND BIOSENSORS TO INCREASE DEMAND FOR SPECIALIZED SYNTHESIS, MODIFICATION, AND CONJUGATION SERVICES
14.6 CLINICAL & DIAGNOSTIC LABORATORIES
14.6.1 ASSAY STANDARDIZATION AND CLINICAL-GRADE QUALITY REQUIREMENTS TO SUPPORT OUTSOURCED PEPTIDE SERVICES FOR DIAGNOSTIC LABORATORIES
15 PEPTIDE SYNTHESIS MARKET, BY APPLICATION
15.1 INTRODUCTION
15.2 THERAPEUTIC APPLICATIONS
15.2.1 THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION
15.2.1.1 Diabetes
15.2.1.1.1 Large established peptide classes and sustained need for high-purity analogs drive growth
15.2.1.2 Obesity
15.2.1.2.1 Late-stage dual- and triple-agonist pipelines and rapid commercial scale-up to make obesity fastest-growing therapeutic indication
15.2.1.3 Cancer
15.2.1.3.1 Targeted delivery, neoantigen programs, and radioligand development to deepen peptide-synthesis requirements in oncology
15.2.1.4 Autoimmune disease
15.2.1.4.1 Targeted oral peptides and antigen-specific immunomodulation to broaden peptide use in chronic autoimmune disorders
15.2.1.5 Other therapeutic indications
15.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE
15.2.2.1 Metabolic & hormonal peptides
15.2.2.1.1 High-volume incretin, insulin, and hormone-peptide demand to drive market growth
15.2.2.2 Peptide inhibitors
15.2.2.2.1 Improved oral delivery, structural constraint, and access to difficult protein interfaces to expand peptide inhibitor development
15.2.2.3 Peptide-drug conjugates (PDCs)
15.2.2.3.1 Targeted payload delivery and radioconjugate pipelines to make PDCs fastest-growing therapeutic molecule category
15.2.2.4 Peptide-based vaccines
15.2.2.4.1 Neoepitope discovery, immune monitoring, and personalized vaccine strategies to support high-diversity peptide synthesis demand
15.2.2.5 Other therapeutic modalities
15.3 RESEARCH APPLICATIONS
15.3.1 HIGH-THROUGHPUT DISCOVERY, BIOMARKER STUDIES, AND RECURRING CUSTOM-PEPTIDE USE TO SUSTAIN BROAD RESEARCH DEMAND BASE
15.4 DIAGNOSTIC APPLICATIONS
15.4.1 PEPTIDE-BASED ASSAY REAGENTS, IMAGING LIGANDS, AND COMPANION-DIAGNOSTIC DEVELOPMENT TO EXPAND SPECIALIZED DIAGNOSTIC DEMAND
16 PEPTIDE SYNTHESIS MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 US
16.2.1.1 Dense peptide pipelines and domestic capacity to sustain market growth
16.2.2 CANADA
16.2.2.1 Biopharma manufacturing investment and research demand to support steady expansion
16.3 EUROPE
16.3.1 GERMANY
16.3.1.1 Integrated peptide manufacturing and strong chemical supply chains to support demand
16.3.2 UK
16.3.2.1 Research intensity and diagnostic peptide capability to support specialized demand
16.3.3 FRANCE
16.3.3.1 Expanding SPPS capacity to strengthen commercial peptide supply base
16.3.4 ITALY
16.3.4.1 Injectable manufacturing integration to support peptide development-to-product workflows
16.3.5 SPAIN
16.3.5.1 Research and specialty-pharma activity to sustain demand for imported synthesis solutions
16.3.6 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 CHINA
16.4.1.1 Large-scale TIDES capacity and domestic supplier depth to accelerate market expansion
16.4.2 JAPAN
16.4.2.1 Advanced drug discovery and specialty peptide innovation to sustain high-value demand
16.4.3 INDIA
16.4.3.1 Cost-efficient CRDMO expansion and new peptide capacity to accelerate market growth
16.4.4 SOUTH KOREA
16.4.4.1 Biotech investment and long-acting peptide development to expand specialized demand
16.4.5 AUSTRALIA
16.4.5.1 Research-intensive institutions and biotech pipelines to sustain high-value peptide demand
16.4.6 REST OF ASIA PACIFIC
16.5 LATIN AMERICA
16.5.1 BRAZIL
16.5.1.1 Large research base and metabolic-disease focus to make Brazil core Latin American market
16.5.2 MEXICO
16.5.2.1 US-linked manufacturing and clinical research to support peptide synthesis demand
16.5.3 REST OF LATIN AMERICA
16.6 MIDDLE EAST
16.6.1 GCC COUNTRIES
16.6.1.1 Saudi Arabia
16.6.1.1.1 Localization initiatives and research funding to support rising peptide workflow adoption
16.6.1.2 UAE
16.6.1.2.1 Biotech hubs and regional distribution to strengthen access to peptide synthesis solutions
16.6.1.3 Rest of GCC Countries
16.6.2 REST OF MIDDLE EAST
16.7 AFRICA
16.7.1 RESEARCH-LED DEMAND AND IMPORT DEPENDENCE TO SHAPE MARKET
17 COMPETITIVE LANDSCAPE
17.1 OVERVIEW
17.2 KEY PLAYER STRATEGY/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
17.3 REVENUE ANALYSIS, 2021–2025
17.4 MARKET SHARE ANALYSIS, 2025
17.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Offering footprint
17.5.5.4 Product type footprint
17.5.5.5 Application footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of key startups/SMEs
17.7 COMPANY VALUATION & FINANCIAL METRICS
17.7.1 FINANCIAL METRICS
17.7.2 COMPANY VALUATION
17.8 PRODUCT/SERVICE COMPARISON
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT LAUNCHES
17.9.2 DEALS
17.9.3 EXPANSIONS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 THERMO FISHER SCIENTIFIC INC.
18.1.1.1 Business overview
18.1.1.2 Products & services offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches
18.1.1.3.2 Deals
18.1.1.3.3 Expansions
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses & competitive threats
18.1.2 MERCK KGAA
18.1.2.1 Business overview
18.1.2.2 Products & services offered
18.1.2.3 Recent developments
18.1.2.3.1 Deals
18.1.2.3.2 Expansions
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 AGILENT TECHNOLOGIES, INC.
18.1.3.1 Business overview
18.1.3.2 Products & services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses and competitive threats
18.1.4 GENSCRIPT BIOTECH CORPORATION
18.1.4.1 Business overview
18.1.4.2 Products & services offered
18.1.4.3 Recent developments
18.1.4.3.1 Expansions
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 KANEKA CORPORATION
18.1.5.1 Business overview
18.1.5.2 Products & services offered
18.1.5.3 Recent developments
18.1.5.3.1 Expansions
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 SARTORIUS AG
18.1.6.1 Business overview
18.1.6.2 Products & services offered
18.1.6.3 Recent developments
18.1.6.3.1 Expansions
18.1.7 BACHEM HOLDING AG
18.1.7.1 Business overview
18.1.7.2 Products & services offered
18.1.7.3 Recent developments
18.1.7.3.1 Deals
18.1.7.3.2 Expansions
18.1.8 BIOTAGE AB
18.1.8.1 Business overview
18.1.8.2 Products & services offered
18.1.8.3 Recent developments
18.1.8.3.1 Product launches
18.1.8.3.2 Deals
18.1.9 CEM CORPORATION
18.1.9.1 Business overview
18.1.9.2 Products & services offered
18.1.9.3 Recent developments
18.1.9.3.1 Product launches
18.1.10 BIO-SYNTHESIS, INC.
18.1.10.1 Business overview
18.1.10.2 Products & services offered
18.1.11 BIOSYNTH
18.1.11.1 Business overview
18.1.11.2 Products & services offered
18.1.11.3 Recent developments
18.1.11.3.1 Deals
18.1.11.3.2 Expansions
18.1.12 CSBIO
18.1.12.1 Business overview
18.1.12.2 Products & services offered
18.1.13 GL BIOCHEM (SHANGHAI) LTD.
18.1.13.1 Business overview
18.1.13.2 Products & services offered
18.1.14 MESA LABORATORIES, INC.
18.1.14.1 Business overview
18.1.14.2 Products & services offered
18.1.14.3 Recent developments
18.1.14.3.1 Product & service launches
18.1.14.3.2 Deals
18.1.15 DANAHER CORPORATION
18.1.15.1 Business overview
18.1.15.2 Products & services offered
18.1.15.3 Recent developments
18.1.15.3.1 Product launches
18.2 OTHER PLAYERS
18.2.1 CHEM-IMPEX INTERNATIONAL, INC.
18.2.2 ADVANCED CHEMTECH
18.2.3 MIMOTOPES PTY LTD.
18.2.4 IRIS BIOTECH GMBH
18.2.5 AAPPTEC, LLC
18.2.6 ENAMINE LTD.
18.2.7 INTAVIS PEPTIDE SERVICES GMBH
18.2.8 JPT PEPTIDE TECHNOLOGIES GMBH
18.2.9 INNOVAGEN AB
18.2.10 PEPTIDE PROTEIN RESEARCH LTD.
18.2.11 LIFETEIN LLC
18.2.12 CREATIVE PEPTIDES
18.2.13 GENEMED SYNTHESIS, INC.
18.2.14 CHINAPEPTIDES CO., LTD.
18.2.15 BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO.
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.1.1 SECONDARY DATA
19.1.1.1 Key secondary sources
19.1.1.2 Key data from secondary research
19.1.2 PRIMARY DATA
19.1.2.1 Key primary participants
19.1.2.2 Breakdown of primary interviews
19.1.2.3 Key data from primary sources
19.2 MARKET SIZE ESTIMATION
19.2.1 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
19.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
19.2.1.2 Approach 2: Primary research
19.2.1.2.1 Key industry insights
19.2.1.3 Approach 3: MnM repository analysis
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
19.3 MARKET GROWTH RATE PROJECTIONS
19.4 DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PEPTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 GLOBAL PEPTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3 LIST OF SOME LATE-STAGE PEPTIDE THERAPEUTICS
TABLE 4 PEPTIDE SYNTHESIS MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 5 PEPTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
TABLE 9 IMPORT DATA FOR HS CODE 902720, 2021–2025 (UNITS)
TABLE 10 EXPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
TABLE 11 EXPORT DATA FOR HS CODE 902720, 2021–2025 (TONS)
TABLE 12 IMPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
TABLE 13 IMPORT DATA FOR HS CODE 841933, 2022–2025 (UNITS)
TABLE 14 EXPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
TABLE 15 EXPORT DATA FOR HS CODE 841933, 2022–2025 (TONS)
TABLE 16 PEPTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 17 PEPTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
TABLE 19 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING TYPE (%)
TABLE 25 KEY BUYING CRITERIA, BY END USER
TABLE 26 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 27 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 29 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 42 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 50 PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 EUROPE: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 ASIA PACIFIC: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 LATIN AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 MIDDLE EAST: AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 GCC COUNTRIES: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 NORTH AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 EUROPE: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ASIA PACIFIC: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 LATIN AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 MIDDLE EAST: RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 GCC COUNTRIES: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 EUROPE: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 MIDDLE EAST: COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 GCC COUNTRIES: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST: LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 GCC COUNTRIES: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST: PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 GCC COUNTRIES: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST: CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 GCC COUNTRIES: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 MIDDLE EAST: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 PEPTIDE SYNTHESIS INSTRUMENTS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
TABLE 122 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130 PEPTIDE SYNTHESIZERS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
TABLE 131 PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139 PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 140 AUTOMATED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 141 AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 LATIN AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 MIDDLE EAST: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 GCC COUNTRIES: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MANUAL PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 149 MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 ASIA PACIFIC: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 LATIN AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 MIDDLE EAST: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 GCC COUNTRIES: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 157 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 MIDDLE EAST: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 GCC COUNTRIES: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 165 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 MIDDLE EAST: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MIDDLE EAST: OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 LATIN AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 MIDDLE EAST: PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MIDDLE EAST: LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 213 GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
TABLE 215 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 223 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 LATIN AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 252 RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 NORTH AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 EUROPE: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 ASIA PACIFIC: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LATIN AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 MIDDLE EAST: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 GCC COUNTRIES: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 NORTH AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 EUROPE: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 ASIA PACIFIC: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 LATIN AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 MIDDLE EAST: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 265 GCC COUNTRIES: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 267 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 303 CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 304 NORTH AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 EUROPE: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 ASIA PACIFIC: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 LATIN AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308 MIDDLE EAST: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 309 GCC COUNTRIES: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 311 NORTH AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 EUROPE: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 313 ASIA PACIFIC: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 LATIN AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315 MIDDLE EAST: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 316 GCC COUNTRIES: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 318 NORTH AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 EUROPE: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 320 ASIA PACIFIC: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321 LATIN AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 322 MIDDLE EAST: PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 323 GCC COUNTRIES: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 324 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 325 NORTH AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326 EUROPE: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 327 ASIA PACIFIC: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328 LATIN AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 329 MIDDLE EAST: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 330 GCC COUNTRIES: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 332 NORTH AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 333 EUROPE: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 334 ASIA PACIFIC: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 335 LATIN AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336 MIDDLE EAST: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 337 GCC COUNTRIES: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 339 PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 1 PEPTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 GLOBAL PEPTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3 LIST OF SOME LATE-STAGE PEPTIDE THERAPEUTICS
TABLE 4 PEPTIDE SYNTHESIS MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 5 PEPTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
TABLE 9 IMPORT DATA FOR HS CODE 902720, 2021–2025 (UNITS)
TABLE 10 EXPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
TABLE 11 EXPORT DATA FOR HS CODE 902720, 2021–2025 (TONS)
TABLE 12 IMPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
TABLE 13 IMPORT DATA FOR HS CODE 841933, 2022–2025 (UNITS)
TABLE 14 EXPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
TABLE 15 EXPORT DATA FOR HS CODE 841933, 2022–2025 (TONS)
TABLE 16 PEPTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 17 PEPTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
TABLE 19 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING TYPE (%)
TABLE 25 KEY BUYING CRITERIA, BY END USER
TABLE 26 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 27 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 28 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 29 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 42 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 50 PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 EUROPE: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 ASIA PACIFIC: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 LATIN AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 MIDDLE EAST: AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 GCC COUNTRIES: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 NORTH AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 EUROPE: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ASIA PACIFIC: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 LATIN AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 MIDDLE EAST: RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 GCC COUNTRIES: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 EUROPE: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 MIDDLE EAST: COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 GCC COUNTRIES: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST: LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 GCC COUNTRIES: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST: PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 99 GCC COUNTRIES: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST: CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 GCC COUNTRIES: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 MIDDLE EAST: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 PEPTIDE SYNTHESIS INSTRUMENTS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
TABLE 122 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130 PEPTIDE SYNTHESIZERS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
TABLE 131 PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 137 GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139 PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 140 AUTOMATED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 141 AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 LATIN AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 MIDDLE EAST: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 GCC COUNTRIES: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 MANUAL PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 149 MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EUROPE: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 ASIA PACIFIC: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 LATIN AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 MIDDLE EAST: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 GCC COUNTRIES: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 157 CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 MIDDLE EAST: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 GCC COUNTRIES: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
TABLE 165 MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 MIDDLE EAST: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 GCC COUNTRIES: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 MIDDLE EAST: OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 GCC COUNTRIES: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187 NORTH AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 ASIA PACIFIC: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 LATIN AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 MIDDLE EAST: PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 GCC COUNTRIES: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 199 GCC COUNTRIES: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 201 NORTH AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 EUROPE: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 ASIA PACIFIC: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 LATIN AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 MIDDLE EAST: LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 GCC COUNTRIES: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 213 GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
TABLE 215 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 CHEMICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 223 SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 LATIN AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 252 RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 NORTH AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 EUROPE: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 ASIA PACIFIC: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LATIN AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 MIDDLE EAST: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 GCC COUNTRIES: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 NORTH AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 EUROPE: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 ASIA PACIFIC: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 LATIN AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 MIDDLE EAST: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 265 GCC COUNTRIES: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 267 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 273 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 303 CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 304 NORTH AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 EUROPE: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 ASIA PACIFIC: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 LATIN AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308 MIDDLE EAST: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 309 GCC COUNTRIES: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 311 NORTH AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 EUROPE: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 313 ASIA PACIFIC: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 LATIN AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315 MIDDLE EAST: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 316 GCC COUNTRIES: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 318 NORTH AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 EUROPE: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 320 ASIA PACIFIC: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321 LATIN AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 322 MIDDLE EAST: PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 323 GCC COUNTRIES: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 324 PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 325 NORTH AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326 EUROPE: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 327 ASIA PACIFIC: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328 LATIN AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 329 MIDDLE EAST: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 330 GCC COUNTRIES: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331 PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 332 NORTH AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 333 EUROPE: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 334 ASIA PACIFIC: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 335 LATIN AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336 MIDDLE EAST: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 337 GCC COUNTRIES: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 339 PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 PEPTIDE SYNTHESIS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 PEPTIDE SYNTHESIS MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL PEPTIDE SYNTHESIS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PEPTIDE SYNTHESIS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN PEPTIDE SYNTHESIS MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PEPTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 SURGING DEMAND FOR GLP-1 AND OTHER PEPTIDE THERAPEUTICS TO DRIVE MARKET GROWTH
FIGURE 10 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF PEPTIDE SYNTHESIS MARKET IN NORTH AMERICA IN 2025
FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL PEPTIDE SYNTHESIS MARKET DURING FORECAST PERIOD
FIGURE 12 THERAPEUTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 PEPTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 PEPTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 PEPTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 PEPTIDE SYNTHESIS MARKET ECOSYSTEM
FIGURE 17 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TYPE, 2023–2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS, 2015–2025
FIGURE 21 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 23 KEY BUYING CRITERIA, BY END USER
FIGURE 24 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2021–2025 (USD MILLION)
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2025
FIGURE 28 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 PEPTIDE SYNTHESIS MARKET: COMPANY FOOTPRINT
FIGURE 30 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 EV/EBITDA OF KEY VENDORS
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 PEPTIDE SYNTHESIS MARKET: PRODUCT/SERVICE COMPARATIVE ANALYSIS
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 38 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 40 BACHEM HOLDING AG: COMPANY SNAPSHOT (2025)
FIGURE 41 MESA LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 PEPTIDE SYNTHESIS MARKET: RESEARCH DESIGN
FIGURE 44 PEPTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 45 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
FIGURE 46 PEPTIDE SYNTHESIS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
FIGURE 47 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025)
FIGURE 48 PEPTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 49 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 50 PEPTIDE SYNTHESIS MARKET: CAGR PROJECTIONS
FIGURE 51 PEPTIDE SYNTHESIS MARKET: DATA TRIANGULATION
FIGURE 1 PEPTIDE SYNTHESIS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 PEPTIDE SYNTHESIS MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL PEPTIDE SYNTHESIS MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PEPTIDE SYNTHESIS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN PEPTIDE SYNTHESIS MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PEPTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 SURGING DEMAND FOR GLP-1 AND OTHER PEPTIDE THERAPEUTICS TO DRIVE MARKET GROWTH
FIGURE 10 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF PEPTIDE SYNTHESIS MARKET IN NORTH AMERICA IN 2025
FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL PEPTIDE SYNTHESIS MARKET DURING FORECAST PERIOD
FIGURE 12 THERAPEUTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 PEPTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 PEPTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 PEPTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 PEPTIDE SYNTHESIS MARKET ECOSYSTEM
FIGURE 17 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TYPE, 2023–2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS, 2015–2025
FIGURE 21 IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 23 KEY BUYING CRITERIA, BY END USER
FIGURE 24 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2021–2025 (USD MILLION)
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2025
FIGURE 28 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 PEPTIDE SYNTHESIS MARKET: COMPANY FOOTPRINT
FIGURE 30 PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 EV/EBITDA OF KEY VENDORS
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 PEPTIDE SYNTHESIS MARKET: PRODUCT/SERVICE COMPARATIVE ANALYSIS
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 38 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 40 BACHEM HOLDING AG: COMPANY SNAPSHOT (2025)
FIGURE 41 MESA LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 43 PEPTIDE SYNTHESIS MARKET: RESEARCH DESIGN
FIGURE 44 PEPTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 45 GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
FIGURE 46 PEPTIDE SYNTHESIS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
FIGURE 47 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025)
FIGURE 48 PEPTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 49 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 50 PEPTIDE SYNTHESIS MARKET: CAGR PROJECTIONS
FIGURE 51 PEPTIDE SYNTHESIS MARKET: DATA TRIANGULATION
